ZEUS 和 HORIZON 试验结果:心血管疾病治疗无显著差异
STAT+: Heart association meeting’s readout is trending ‘neutral’
ZEUS 和 HORIZON 两项针对心血管疾病的临床试验均未显示治疗组与安慰剂组之间存在显著差异。这两项研究虽然结果“中性”,但仍提供了宝贵的研究教训。
Trials finding interventions made no difference still teach valuable lessons, experts say
![]()
CHICAGO — If one word could describe research presented at this year’s American Heart Association scientific sessions, it might be “neutral.”
The meeting began with two blockbuster disappointments, hinted at in top-line results released weeks or months ago but detailed with unvarnished specificity Saturday morning. The ZEUS trial targeting inflammation showed no difference between the treatment and placebo arms. The HORIZON trial taking aim at lipoprotein(a) also revealed nearly identical results, whether participants were on or off the drug.
In other words, neutral.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
-
Cardiovascular Disease Reporter
Liz covers cardiovascular and metabolic disease, asking why we’re not doing better or even losing ground against the world’s leading killer. Send tips on Signal at LizC.22.
来源:STAT 主站 · statnews.com